Rubric Capital Management (New York)’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Rubric Capital Management (New York)’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,844	Closed	-$30.7K	–	80
2024 Q4	$30.7K	Hold	5,844	–	–	﹤0.01%	69
2024 Q3	$83.7K	Hold	5,844	–	–	﹤0.01%	65
2024 Q2	$94.7K	Hold	5,844	–	–	﹤0.01%	68
2024 Q1	$591K	Sell	5,844 -11,875	-67%	-$750K	0.02%	68
2023 Q4	$418K	Hold	17,719	–	–	0.01%	57
2023 Q3	$358K	Hold	17,719	–	–	0.01%	61
2023 Q2	$461K	Sell	17,719 -1,617	-8%	-$46.3K	0.02%	61
2023 Q1	$402K	Hold	19,336	–	–	0.01%	71
2022 Q4	$394K	Sell	19,336 -86,014	-82%	-$1.62M	0.02%	95
2022 Q3	$2.91M	Hold	105,350	–	–	0.15%	74
2022 Q2	$2.78M	Hold	105,350	–	–	0.15%	74
2022 Q1	$8.43M	Buy	105,350 +26,038	+33%	+$3.22M	0.3%	51
2021 Q4	$16.2M	Buy	79,312 +13,692	+21%	+$3.42M	0.76%	38
2021 Q3	$21.2M	Buy	65,620 +38,937	+146%	+$11.4M	0.59%	36
2021 Q2	$6.93M	Buy	+26,683	New	+$8.13M	0.44%	44
2020 Q4	–	Sell	-995	Closed	-$247K	–	85
2020 Q3	$247K	Buy	+995	New	+$202K	0.02%	63

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rubric Capital Management (New York)'s VINC Position: Q1 2025 in Review

Rubric Capital Management (New York) sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 5,844 shares — an estimated $30.7K sold.

Rubric Capital Management (New York) first reported a position in VINC in Q3 2020 and held it in 16 quarters. The position peaked at $21.2M in Q3 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

Rubric Capital Management (New York) reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Rubric Capital Management (New York) sold 5,844 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $30.7K.
Rubric Capital Management (New York) first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2020 and held it in 16 quarters.
Rubric Capital Management (New York)'s Vincerx Pharma, Inc. Common Stock position peaked at $21.2M in Q3 2021.
14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q1 2025, filed 14 May 2025.